Activation‐induced marker (AIM) assays have proven to be an accessible and rapid means
of antigen‐specific T‐cell detection. The method typically involves short‐term incubation of …

Immunotherapy targeting the autoimmune process in type 1 diabetes (T1D) can delay the
loss of β-cells but needs to have minimal adverse effects to be an adjunct to insulin in the …

Type 1 diabetes (T1D) results from the destruction of pancreatic beta cells through a process
that is primarily mediated by T cells. Emerging evidence suggests that dendritic cells (DCs) …

It has been 100 years since the life-saving discovery of insulin, yet daily management of type
1 diabetes (T1D) remains challenging. Even with closed-loop systems, the prevailing need …

Hyperglycemia, a hallmark of diabetes and various metabolic disorders, has profound
implications for immune cell function. The relationship between elevated blood glucose …

Use of immunomodulating agents to prevent the progression of autoimmune β-cell damage
leading to type 1 diabetes mellitus (T1DM) is an interesting area for research. These include …

Cytometric immunophenotyping is a powerful tool to discover and implement T‐cell
biomarkers of type 1 diabetes (T1D) progression and response to clinical therapy. Although …

The chemokine receptor CXCR3 and its ligands (MIG/CXCL9, IP-10/CXCL10, and I-
TAC/CXCL11) play a central role in the generation of cellular inflammation, both in the …

Interleukin (IL)-23, an IL-12 cytokine family member, is a hierarchically dominant regulatory
cytokine in a cluster of immune-mediated inflammatory diseases (IMIDs), including psoriasis …

One vision-threatening side effect of systematic diabetes mellitus is diabetic retinopathy
(DR). Recent studies have revealed that the development and progression of DR depend …